Format

Send to

Choose Destination
Otolaryngol Head Neck Surg. 2001 Apr;124(4):426-32.

A novel CD44 v3 isoform is involved in head and neck squamous cell carcinoma progression.

Author information

1
Department of Otolaryngology, School of Medicine, University of Miami, FL 33101, USA. efranzman@med.miami.edu

Abstract

OBJECTIVES:

CD44 comprises a family of isoforms involved in tumorigenesis. Here we investigate the role of CD44 isoforms in head and neck squamous cell carcinoma (HNSCC) progression.

MATERIALS AND METHODS:

HNSCC specimens underwent reverse transcriptase-polymerase chain reaction (RT-PCR) followed by Southern blot analysis. After surface biotinylation, FaDu (hypopharyngeal HNSCC) and CD44v3-transfected COS-7 cells were CD44 antibody-precipitated and compared by Western blot analysis. FaDu cells underwent double immunofluorescence staining and growth assays.

RESULTS:

Southern blot analysis suggested differential CD44v3 isoform expression in tumor and normal tissue. Cloning and sequencing revealed 2 novel CD44v isoforms. Western blot analysis suggested CD44v3 expression in COS-7 transfectants and FaDu. Double immunofluorescence staining revealed co-localization of CD44v3 and actin in FaDu projections. Anti-CD44v3 antibody decreased FaDu growth.

CONCLUSION:

HNSCC tissue and FaDu appear to express CD44v3 isoforms. These isoforms may promote tumorigenesis.

CLINICAL SIGNIFICANCE:

CD44v3 isoforms may be effective tumor markers and targets for HNSCC therapy.

PMID:
11283501
DOI:
10.1067/mhn.2001.114674
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center